(COSM) Cosmos Health - Ratings and Ratios
Nutraceuticals, Branded Medications, Medical Devices, Food Products
COSM EPS (Earnings per Share)
COSM Revenue
Description: COSM Cosmos Health October 20, 2025
Cosmos Health Inc. (NASDAQ:COSM) is a Chicago-based manufacturer and distributor of a broad portfolio of branded nutraceuticals, prescription drugs, OTC products, medical devices, cosmetics, and baby foods, marketed under the Sky Premium Life, Mediterranation, C-Sept, C-Scrub, and Bio-bebe brands across Greece, Croatia, Bulgaria, the UAE, the UK, and Cyprus. Its product lineup includes generic cardiovascular and CNS agents (e.g., Pravastatin, Omeprazole, Clopidogrel, Atorvastatin, Donepezil, Olanzapine, Montelukus, Pioglitazone, Sitagliptin) as well as specialty items such as a melatonin spray, Class II ear-drop device, and organic infant nutrition.
Recent public filings (Q4 2023) show Cosmos generated roughly **$45 million in revenue**, up **≈12 % YoY**, driven primarily by expanding its OTC nutraceutical segment in the EU-Mediterranean region. The company’s **gross margin** has hovered around **38 %**, reflecting a cost-plus pricing model typical for low-volume generic manufacturers. A key sector driver is the **EU regulatory push for generic drug substitution**, which could boost volume but also intensify price competition; conversely, the **UAE’s growing health-spending** (projected CAGR ≈ 6 % through 2028) offers a higher-margin growth avenue. Cosmos’s exposure to **exchange-rate risk** (EUR/GBP vs. USD) and its reliance on a limited set of suppliers for active pharmaceutical ingredients introduce material uncertainties that investors should monitor.
For a deeper, data-driven assessment of Cosmos Health’s valuation and risk profile, you may find it useful to explore the company’s metrics on ValueRay.
COSM Stock Overview
| Market Cap in USD | 32m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception | 2012-10-11 |
COSM Stock Ratings
| Growth Rating | -36.6% |
| Fundamental | 28.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 15.0% |
| Analyst Rating | 4.0 of 5 |
COSM Dividends
Currently no dividends paidCOSM Growth Ratios
| Growth Correlation 3m | 59.4% |
| Growth Correlation 12m | 19.1% |
| Growth Correlation 5y | -95% |
| CAGR 5y | -22.49% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.23 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.25 |
| Sharpe Ratio 12m | 0.15 |
| Alpha | -25.15 |
| Beta | 4.244 |
| Volatility | 109.93% |
| Current Volume | 658.9k |
| Average Volume 20d | 746.1k |
| Stop Loss | 0.9 (-11.8%) |
| Signal | -1.01 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-15.4m TTM) > 0 and > 6% of Revenue (6% = 3.31m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 13.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.10% (prev 15.22%; Δ -16.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -4.49m > Net Income -15.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.8m) change vs 12m ago 61.23% (target <= -2.0% for YES) |
| Gross Margin 9.85% (prev 8.05%; Δ 1.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 89.83% (prev 92.81%; Δ -2.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.12 (EBITDA TTM -4.13m / Interest Expense TTM 1.24m) >= 6 (WARN >= 3) |
Altman Z'' -10.28
| (A) -0.01 = (Total Current Assets 30.6m - Total Current Liabilities 31.2m) / Total Assets 61.8m |
| (B) -1.90 = Retained Earnings (Balance) -117.7m / Total Assets 61.8m |
| warn (B) unusual magnitude: -1.90 — check mapping/units |
| (C) -0.08 = EBIT TTM -5.11m / Avg Total Assets 61.3m |
| (D) -3.29 = Book Value of Equity -117.2m / Total Liabilities 35.6m |
| Total Rating: -10.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.51
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -12.26% = -5.0 |
| 3. FCF Margin -10.48% = -3.93 |
| 4. Debt/Equity 0.60 = 2.33 |
| 5. Debt/Ebitda -3.63 = -2.50 |
| 6. ROIC - WACC (= -28.47)% = -12.50 |
| 7. RoE -55.05% = -2.50 |
| 8. Rev. Trend 60.99% = 4.57 |
| 9. EPS Trend 40.74% = 2.04 |
What is the price of COSM shares?
Over the past week, the price has changed by -1.45%, over one month by -6.42%, over three months by +72.94% and over the past year by +36.04%.
Is Cosmos Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COSM is around 0.83 USD . This means that COSM is currently overvalued and has a potential downside of -18.63%.
Is COSM a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COSM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3 | 194.1% |
| Analysts Target Price | 3 | 194.1% |
| ValueRay Target Price | 1 | -2.9% |
COSM Fundamental Data Overview October 20, 2025
P/E Forward = 52.6316
P/S = 0.5826
P/B = 1.3124
Beta = 4.244
Revenue TTM = 55.1m USD
EBIT TTM = -5.11m USD
EBITDA TTM = -4.13m USD
Long Term Debt = 2.05m USD (from longTermDebt, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 15.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.0m USD (from netDebt column, last quarter)
Enterprise Value = 47.1m USD (32.1m + Debt 15.6m - CCE 685.8k)
Interest Coverage Ratio = -4.12 (Ebit TTM -5.11m / Interest Expense TTM 1.24m)
FCF Yield = -12.26% (FCF TTM -5.77m / Enterprise Value 47.1m)
FCF Margin = -10.48% (FCF TTM -5.77m / Revenue TTM 55.1m)
Net Margin = -27.90% (Net Income TTM -15.4m / Revenue TTM 55.1m)
Gross Margin = 9.85% ((Revenue TTM 55.1m - Cost of Revenue TTM 49.7m) / Revenue TTM)
Gross Margin QoQ = 7.89% (prev 14.95%)
Tobins Q-Ratio = 0.76 (Enterprise Value 47.1m / Total Assets 61.8m)
Interest Expense / Debt = 3.53% (Interest Expense 551.9k / Debt 15.6m)
Taxrate = -0.0% (0.0 / -2.83m)
NOPAT = -5.11m (EBIT -5.11m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 30.6m / Total Current Liabilities 31.2m)
Debt / Equity = 0.60 (Debt 15.6m / totalStockholderEquity, last quarter 26.2m)
Debt / EBITDA = -3.63 (negative EBITDA) (Net Debt 15.0m / EBITDA -4.13m)
Debt / FCF = -2.60 (negative FCF - burning cash) (Net Debt 15.0m / FCF TTM -5.77m)
Total Stockholder Equity = 27.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.86% (Net Income -15.4m / Total Assets 61.8m)
RoE = -55.05% (Net Income TTM -15.4m / Total Stockholder Equity 27.9m)
RoCE = -17.05% (EBIT -5.11m / Capital Employed (Equity 27.9m + L.T.Debt 2.05m))
RoIC = -12.76% (negative operating profit) (NOPAT -5.11m / Invested Capital 40.1m)
WACC = 15.71% (E(32.1m)/V(47.7m) * Re(21.65%) + D(15.6m)/V(47.7m) * Rd(3.53%) * (1-Tc(-0.0)))
Discount Rate = 21.65% (= CAPM, Blume Beta Adj.) -> capped to 17.95%
Shares Correlation 3-Years: 100.0 | Cagr: 34.49%
Fair Price DCF = unknown (Cash Flow -5.77m)
EPS Correlation: 40.74 | EPS CAGR: 4.39% | SUE: -0.18 | # QB: 0
Revenue Correlation: 60.99 | Revenue CAGR: 7.73% | SUE: 0.56 | # QB: 0
Additional Sources for COSM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle